Global pharmacogenomics market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 88 tables and 83 figures, this 181-page report “Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region.
Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Genotyping
• SNP Identification
• Diagnostics
• Other Services
Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Electrophoresis
• Mass Spectrometry
• Other Technologies
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oncology
• Infectious Diseases
• Neurology/Psychiatry
• Cardiovascular
• Pain Management
• Other Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Hospitals and Clinics
• Pharmaceutical Companies
• Research Institutes
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
Table 1. Snapshot of Global Pharmacogenomics Market, 2019-2030 20
Table 2. Web-based Resources of Pharmacogenomics 25
Table 3. Main Product Trends and Market Opportunities in Global Pharmacogenomics Market 35
Table 4. Global Pharmacogenomics Market by Service, 2019-2030, $ mn 43
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing 48
Table 6. Global Pharmacogenomics Market by Technology, 2019-2030, $ mn 50
Table 7. Global Pharmacogenomics Market by Application, 2019-2030, $ mn 58
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry 63
Table 9. Global Pharmacogenomics Market by End User, 2019-2030, $ mn 67
Table 10. Global Pharmacogenomics Market by Region, 2019-2030, $ mn 73
Table 11. Total Health Expenditure per capita in PPP International U.S. Dollars by Country 75
Table 12. Leading National Pharmacogenomics Market, 2019 and 2030, $ mn 77
Table 13. North America Pharmacogenomics Market by Country, 2019-2030, $ mn 80
Table 14. U.S. Pharmacogenomics Market by Service, 2019-2030, $ mn 84
Table 15. U.S. Pharmacogenomics Market by Technology, 2019-2030, $ mn 84
Table 16. U.S. Pharmacogenomics Market by Application, 2019-2030, $ mn 84
Table 17. Canada Pharmacogenomics Market by Service, 2019-2030, $ mn 87
Table 18. Canada Pharmacogenomics Market by Technology, 2019-2030, $ mn 87
Table 19. Canada Pharmacogenomics Market by Application, 2019-2030, $ mn 87
Table 20. Mexico Pharmacogenomics Market by Service, 2019-2030, $ mn 89
Table 21. Mexico Pharmacogenomics Market by Technology, 2019-2030, $ mn 89
Table 22. Mexico Pharmacogenomics Market by Application, 2019-2030, $ mn 89
Table 23. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn 93
Table 24. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn 95
Table 25. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn 95
Table 26. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn 95
Table 27. UK Pharmacogenomics Market by Service, 2019-2030, $ mn 97
Table 28. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn 97
Table 29. UK Pharmacogenomics Market by Application, 2019-2030, $ mn 97
Table 30. France Pharmacogenomics Market by Service, 2019-2030, $ mn 99
Table 31. France Pharmacogenomics Market by Technology, 2019-2030, $ mn 99
Table 32. France Pharmacogenomics Market by Application, 2019-2030, $ mn 99
Table 33. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn 101
Table 34. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn 101
Table 35. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn 101
Table 36. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn 103
Table 37. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn 103
Table 38. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn 103
Table 39. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn 105
Table 40. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn 105
Table 41. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn 105
Table 42. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn 107
Table 43. APAC Pharmacogenomics Market by Country, 2019-2030, $ mn 110
Table 44. Japan Pharmacogenomics Market by Service, 2019-2030, $ mn 114
Table 45. Japan Pharmacogenomics Market by Technology, 2019-2030, $ mn 114
Table 46. Japan Pharmacogenomics Market by Application, 2019-2030, $ mn 114
Table 47. China Pharmacogenomics Market by Service, 2019-2030, $ mn 116
Table 48. China Pharmacogenomics Market by Technology, 2019-2030, $ mn 116
Table 49. China Pharmacogenomics Market by Application, 2019-2030, $ mn 116
Table 50. Australia Pharmacogenomics Market by Service, 2019-2030, $ mn 118
Table 51. Australia Pharmacogenomics Market by Technology, 2019-2030, $ mn 118
Table 52. Australia Pharmacogenomics Market by Application, 2019-2030, $ mn 118
Table 53. India Pharmacogenomics Market by Service, 2019-2030, $ mn 120
Table 54. India Pharmacogenomics Market by Technology, 2019-2030, $ mn 120
Table 55. India Pharmacogenomics Market by Application, 2019-2030, $ mn 120
Table 56. South Korea Pharmacogenomics Market by Service, 2019-2030, $ mn 122
Table 57. South Korea Pharmacogenomics Market by Technology, 2019-2030, $ mn 122
Table 58. South Korea Pharmacogenomics Market by Application, 2019-2030, $ mn 122
Table 59. Pharmacogenomics Market in Rest of APAC by Country, 2019-2030, $ mn 124
Table 60. South America Pharmacogenomics Market by Country, 2019-2030, $ mn 127
Table 61. Argentina Pharmacogenomics Market by Service, 2019-2030, $ mn 129
Table 62. Argentina Pharmacogenomics Market by Technology, 2019-2030, $ mn 129
Table 63. Argentina Pharmacogenomics Market by Application, 2019-2030, $ mn 129
Table 64. Brazil Pharmacogenomics Market by Service, 2019-2030, $ mn 131
Table 65. Brazil Pharmacogenomics Market by Technology, 2019-2030, $ mn 131
Table 66. Brazil Pharmacogenomics Market by Application, 2019-2030, $ mn 131
Table 67. Chile Pharmacogenomics Market by Service, 2019-2030, $ mn 133
Table 68. Chile Pharmacogenomics Market by Technology, 2019-2030, $ mn 133
Table 69. Chile Pharmacogenomics Market by Application, 2019-2030, $ mn 133
Table 70. MEA Pharmacogenomics Market by Country, 2019-2030, $ mn 137
Table 71. UAE Pharmacogenomics Market by Service, 2019-2030, $ mn 139
Table 72. UAE Pharmacogenomics Market by Technology, 2019-2030, $ mn 139
Table 73. UAE Pharmacogenomics Market by Application, 2019-2030, $ mn 139
Table 74. Saudi Arabia Pharmacogenomics Market by Service, 2019-2030, $ mn 141
Table 75. Saudi Arabia Pharmacogenomics Market by Technology, 2019-2030, $ mn 141
Table 76. Saudi Arabia Pharmacogenomics Market by Application, 2019-2030, $ mn 141
Table 77. South Africa Pharmacogenomics Market by Service, 2019-2030, $ mn 143
Table 78. South Africa Pharmacogenomics Market by Technology, 2019-2030, $ mn 143
Table 79. South Africa Pharmacogenomics Market by Application, 2019-2030, $ mn 143
Table 80. Product Approvals by Company, January 2016 – April 2019 147
Table 81. Breakdown of Global Market by Key Vendor, 2019, % 147
Table 82. 23andMe, Inc.: Company Snapshot 150
Table 83. 23andMe, Inc.: Business Segmentation 150
Table 84. 23andMe, Inc.: Product Portfolio 151
Table 85. 23andMe, Inc.: Revenue, 2016-2018, $ mn 151
Table 86. 23andMe, Inc.: Recent Developments 151
Table 87. Risk Evaluation for Investing in Global Market, 2019-2030 176
Table 88. Critical Success Factors and Key Takeaways 179
Figure 1. Research Method Flow Chart 13
Figure 2. Breakdown of Primary Research 15
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 19
Figure 5. Global Pharmacogenomics Market, 2019-2030, $ mn 22
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 24
Figure 7. Impact of COVID-19 on Business 26
Figure 8. Primary Drivers and Impact Factors of Global Pharmacogenomics Market 28
Figure 9. World Top 10 Causes of Deaths, 2016 31
Figure 10. Primary Restraints and Impact Factors of Global Pharmacogenomics Market 32
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 34
Figure 12. Investment Opportunity Analysis 36
Figure 13. Porter’s Fiver Forces Analysis of Global Pharmacogenomics Market 39
Figure 14. Breakdown of Global Pharmacogenomics Market by Service, 2019-2030, % of Revenue 43
Figure 15. Global Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 44
Figure 16. Global Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 45
Figure 17. Global Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 46
Figure 18. Global Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 47
Figure 19. Global Pharmacogenomics Market: Other Services, 2019-2030, $ mn 49
Figure 20. Breakdown of Global Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 50
Figure 21. Global Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 51
Figure 22. Global Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 52
Figure 23. Global Pharmacogenomics Market: Microarray, 2019-2030, $ mn 53
Figure 24. Global Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 54
Figure 25. Global Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 55
Figure 26. Global Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 56
Figure 27. Global Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 57
Figure 28. Breakdown of Global Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 58
Figure 29. Global Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 59
Figure 30. Global Pharmacogenomics Market: Oncology, 2019-2030, $ mn 60
Figure 31. Global Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 61
Figure 32. Global Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 62
Figure 33. Global Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 64
Figure 34. Global Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 65
Figure 35. Global Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 66
Figure 36. Breakdown of Global Pharmacogenomics Market by End User, 2019-2030, % of Revenue 67
Figure 37. Global Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 68
Figure 38. Global Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 69
Figure 39. Global Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 70
Figure 40. Global Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 71
Figure 41. Global Market Snapshot by Region 72
Figure 42. Geographic Spread of Worldwide Pharmacogenomics Market, 2019-2030, % of Sales Revenue 73
Figure 43. Global Addressable Market Cap in 2020-2030 by Region, Value ($ mn) and Share (%) 74
Figure 44. Health Spending as a Share of GDP by Country, 2015 and 2030 76
Figure 45. North American Pharmacogenomics Market, 2019-2030, $ mn 79
Figure 46. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 80
Figure 47. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 81
Figure 48. U.S. Pharmacogenomics Market, 2019-2030, $ mn 83
Figure 49. Canada Pharmacogenomics Market, 2019-2030, $ mn 86
Figure 50. Pharmacogenomics Market in Mexico, 2015-2030, $ mn 88
Figure 51. European Pharmacogenomics Market, 2019-2030, $ mn 91
Figure 52. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 92
Figure 53. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 93
Figure 54. Pharmacogenomics Market in Germany, 2019-2030, $ mn 94
Figure 55. Pharmacogenomics Market in UK, 2019-2030, $ mn 96
Figure 56. Pharmacogenomics Market in France, 2019-2030, $ mn 98
Figure 57. Pharmacogenomics Market in Spain, 2019-2030, $ mn 100
Figure 58. Pharmacogenomics Market in Italy, 2019-2030, $ mn 102
Figure 59. Pharmacogenomics Market in Russia, 2019-2030, $ mn 104
Figure 60. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn 106
Figure 61. Asia-Pacific Pharmacogenomics Market, 2019-2030, $ mn 109
Figure 62. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 109
Figure 63. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 111
Figure 64. Pharmacogenomics Market in Japan, 2019-2030, $ mn 113
Figure 65. Pharmacogenomics Market in China, 2019-2030, $ mn 115
Figure 66. Pharmacogenomics Market in Australia, 2019-2030, $ mn 117
Figure 67. Pharmacogenomics Market in India, 2019-2030, $ mn 119
Figure 68. Pharmacogenomics Market in South Korea, 2019-2030, $ mn 121
Figure 69. Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn 123
Figure 70. South America Pharmacogenomics Market, 2019-2030, $ mn 126
Figure 71. Breakdown of South America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 126
Figure 72. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 127
Figure 73. Pharmacogenomics Market in Argentina, 2019-2030, $ mn 128
Figure 74. Pharmacogenomics Market in Brazil, 2019-2030, $ mn 130
Figure 75. Pharmacogenomics Market in Chile, 2019-2030, $ mn 132
Figure 76. Pharmacogenomics Market in Rest of South America, 2019-2030, $ mn 134
Figure 77. Pharmacogenomics Market in Middle East and Africa (MEA), 2019-2030, $ mn 136
Figure 78. Breakdown of MEA Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 136
Figure 79. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 137
Figure 80. Pharmacogenomics Market in UAE, 2019-2030, $ mn 138
Figure 81. Pharmacogenomics Market in Saudi Arabia, 2019-2030, $ mn 140
Figure 82. Pharmacogenomics Market in South Africa, 2019-2030, $ mn 142
Figure 83. Growth Stage of Global Pharmacogenomics Industry over the Forecast Period 145
